Antitumor activity by single agents targeting the Notch signaling pathway, such as a γ-secretase inhibitor and a monoclonal antibody targeting Notch 2/3 receptors, have been observed in early phase clinical trials of sarcoma or desmoid tumors [11, 18–23]. This evidence concerns the gene NOTCH2 and sarcoma.